Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB 9200 in chronic hepatitis B
NCT02751996Phase 2Completed
- Sponsor
- F-star
- Start
- May 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of inarigivir soproxil in Chronic Hepatitis B (CHB) (10 arms), sponsored by F-star. Primary endpoints: Proportion of subjects reporting an adverse event at 12 weeks, HBV DNA decline at 12 weeks and 1 more. Started May 2016; status: completed.
02
Drugs
inarigivir soproxil
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02751996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02751996.